Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age

Inclusion Criteria : * Aged 4-6 years inclusive on the day of inclusion * Child having completed the three-dose vaccination and the booster vaccination with DTacP-IPV//PRP\~T combined vaccine (PENTAXIM™) of the study E2I34 * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedures Exclusion Criteria : * Participation in another clinical trial in the 4 weeks preceding the trial inclusion * Planned participation in another clinical trial during the present trial period * Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances * Chronic illness at a stage that could interfere with trial conduct or completion * Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins) * Any vaccination in the 4 weeks preceding the trial vaccination * History of diphtheria, tetanus, pertussis, poliomyelitis infection (confirmed either clinically, serologically or microbiologically) * Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human immunodeficiency virus (HIV) infection * Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases infection with the trial vaccine or another vaccine after completion of previous study E2I34 * Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * History of/current major neurological diseases or seizures * Febrile illness (temperature ≥ 38°C) or acute illness on the day of inclusion. * Serious or severe reaction after a previous dose of any vaccine containing pertussis antigen, such as * encephalopathy (with or without convulsions) in the 7days following previous administration of a pertussis containing vaccine, * temperature more than 39.5°C within 48 hours following vaccine injection, not due to another identifiable cause * inconsolable crying equal or more than 3 hours within 48 hours following vaccine injection, * hypotonic hyporesponsive episode within 48 hours following vaccine injection, * seizures with or without fever within 3 days following vaccine injection.